CLDN18 and gastric cancer: However, due to the lack of comprehensive clinical information of the chemotherapy treatment outcomes in the large scale of genetic studies in gastric cancer (e.g., TCGA), more independent validation studies are needed to determine the prognostic significance of both SRCC status and CLDN18-ARHGAP, and their impact on determination of personalized treatment strategy.